eBook: Cell and Gene Therapy - 3

Amplify your Viral Vector Production with CRISPR/
Cas9-Engineered STAT1 or BAX KO Cells
Most viral vaccines and AAV vectors for gene therapy are manufactured in large-scale tissue culture systems using
historical cell lines. ATCC is helping boost vaccine and gene therapy by using CRISPR/Cas9 gene editing to create
improved versions of cell lines commonly used for viral manufacturing. These cells produce viruses at titers 10-fold
higher than the corresponding parental cell line, which can significantly reduce costs associated with viral vaccine
and gene therapy production.
Browse www.atcc.org/enhancedvirusproduction to learn more.
Credible leads to Incredible®
©2023 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection
unless indicated otherwise.
These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services or to manufacture
commercial products without prior ATCC written approval.

http://www.atcc.org/enhancedvirusproduction

eBook: Cell and Gene Therapy

Table of Contents for the Digital Edition of eBook: Cell and Gene Therapy